This article was originally published in The Gray Sheet
Executive SummaryEnter into a definitive agreement under which Scherer will provide up to $4.5 mil. in financing to Marquest and will guarantee up to an additional $3 mil. for working capital. Marquest will use the $4.5 mil. for capital additions, to pay off short-term credit and for operating expenses. The firms also will work to refinance Marquest's defaulted Swiss bonds, which amount to about $12.6 mil. The definitive deal's terms are different from those of a March 17 revised agreement in principle ("The Gray Sheet" March 22, p. 21). The March pact would have provided $4.5 mil. in financing, as well as $4.5 mil. through a guarantee of proposed mortgage debt. In conjunction with the agreement's transactions, Scherer may acquire up to about 65% of Marquest common stock and will be able to name the majority of Marquest's board members. Scherer also obtains rights to Marquest's ABG blood gas analysis product line, which it will license back to Marquest. Marquest will have a three-year right to repurchase the product line.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.